# Kenneth F. Grossmann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kenneth-f-grossmann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,100 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 37 |
| i10-index | 67 |
| Last Known Institution | University of Utah |
| OpenAlex ID | https://openalex.org/A5073549408 |
| ORCID iD | https://orcid.org/0000-0002-8523-7407 |
| Works | 369 |

## Researcher papers

- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Gut microbiota and health](https://scholariq.org/topics/gut-microbiota-and-health/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Researcher university

- [University of Utah](https://scholariq.org/institutions/university-of-utah/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.